Everest Medicines Limited (HKG:1952)
Hong Kong
· Delayed Price · Currency is HKD 46.00
+0.35 (0.77%)
Apr 10, 2025, 4:08 PM HKT
Everest Medicines Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Cash & Equivalents | 884.47 | 523.06 | 490.79 | 2,640 | 4,481 | Upgrade
|
| Short-Term Investments | 718.84 | 1,827 | 1,161 | - | 2.08 | Upgrade
|
| Cash & Short-Term Investments | 1,603 | 2,350 | 1,651 | 2,640 | 4,483 | Upgrade
|
| Cash Growth | -31.77% | 42.29% | -37.45% | -41.11% | 4120.60% | Upgrade
|
| Accounts Receivable | 363.57 | 49.86 | 5.21 | 0.05 | - | Upgrade
|
| Other Receivables | 24.69 | 81.96 | 1,681 | 19.52 | 10.91 | Upgrade
|
| Receivables | 388.26 | 131.81 | 1,687 | 19.57 | 10.91 | Upgrade
|
| Inventory | 14.08 | 18.94 | 11.64 | 0.45 | - | Upgrade
|
| Other Current Assets | 9.98 | 7.16 | 64.6 | 27.86 | 2.3 | Upgrade
|
| Total Current Assets | 2,016 | 2,508 | 3,414 | 2,688 | 4,496 | Upgrade
|
| Property, Plant & Equipment | 650.04 | 683.99 | 643.86 | 262.64 | 121.97 | Upgrade
|
| Long-Term Investments | 29.71 | 48.93 | 89.24 | 830.4 | 845.7 | Upgrade
|
| Other Intangible Assets | 2,254 | 2,524 | 2,378 | 2,471 | 2,006 | Upgrade
|
| Other Long-Term Assets | 6.6 | 6.12 | 86.69 | 391.44 | 4.87 | Upgrade
|
| Total Assets | 4,959 | 5,773 | 6,615 | 6,646 | 7,477 | Upgrade
|
| Accounts Payable | 118.69 | 95.48 | 107.52 | 85.66 | 75.1 | Upgrade
|
| Accrued Expenses | 151.36 | 73.51 | 182.07 | 133.79 | 87.62 | Upgrade
|
| Current Portion of Long-Term Debt | 470.21 | 51.28 | 424.08 | - | - | Upgrade
|
| Current Portion of Leases | 18.78 | 18.65 | 20.33 | 28.25 | 19.02 | Upgrade
|
| Other Current Liabilities | 34.5 | 89.82 | 136.03 | 22.56 | 5.18 | Upgrade
|
| Total Current Liabilities | 793.54 | 328.74 | 870.03 | 270.27 | 186.91 | Upgrade
|
| Long-Term Debt | 55.85 | 429.31 | 30.92 | 387.71 | 390.32 | Upgrade
|
| Long-Term Leases | 30.77 | 40 | 59.31 | 95.85 | 58.88 | Upgrade
|
| Long-Term Unearned Revenue | 5.9 | 6.05 | - | - | - | Upgrade
|
| Total Liabilities | 886.05 | 804.1 | 960.26 | 753.83 | 636.11 | Upgrade
|
| Common Stock | 0.22 | 0.22 | 0.21 | 0.2 | 0.2 | Upgrade
|
| Retained Earnings | -10,058 | -9,016 | -8,172 | -7,925 | -6,916 | Upgrade
|
| Treasury Stock | - | -0 | -0 | -58.71 | - | Upgrade
|
| Comprehensive Income & Other | 14,130 | 13,985 | 13,826 | 13,875 | 13,757 | Upgrade
|
| Shareholders' Equity | 4,073 | 4,969 | 5,654 | 5,892 | 6,841 | Upgrade
|
| Total Liabilities & Equity | 4,959 | 5,773 | 6,615 | 6,646 | 7,477 | Upgrade
|
| Total Debt | 575.61 | 539.24 | 534.64 | 511.81 | 468.21 | Upgrade
|
| Net Cash (Debt) | 1,028 | 1,810 | 1,117 | 2,128 | 4,015 | Upgrade
|
| Net Cash Growth | -43.23% | 62.12% | -47.53% | -46.99% | - | Upgrade
|
| Net Cash Per Share | 3.20 | 5.78 | 3.75 | 7.26 | 47.04 | Upgrade
|
| Filing Date Shares Outstanding | 324.35 | 319.36 | 305.46 | 294.41 | 293.22 | Upgrade
|
| Total Common Shares Outstanding | 324.35 | 319.36 | 305.46 | 294.41 | 293.22 | Upgrade
|
| Working Capital | 1,222 | 2,179 | 2,544 | 2,418 | 4,309 | Upgrade
|
| Book Value Per Share | 12.56 | 15.56 | 18.51 | 20.01 | 23.33 | Upgrade
|
| Tangible Book Value | 1,818 | 2,445 | 3,276 | 3,421 | 4,835 | Upgrade
|
| Tangible Book Value Per Share | 5.61 | 7.66 | 10.72 | 11.62 | 16.49 | Upgrade
|
| Buildings | 461.02 | 437.87 | 378.28 | - | - | Upgrade
|
| Machinery | 179.16 | 167.32 | 84.66 | 5.72 | 1.65 | Upgrade
|
| Construction In Progress | - | 9.79 | 45.75 | 102.91 | 5.92 | Upgrade
|
| Leasehold Improvements | 48.17 | 46.9 | 44.77 | 15.91 | 9.98 | Upgrade
|
Updated Aug 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.